|
1
|
Caselmann WH and Alt M: Hepatitis C virus
infection as a major risk factor for hepatocellular carcinoma. J
Hepatol. 24(Suppl): 61–66. 1996.PubMed/NCBI
|
|
2
|
Bartosch B, Thimme R, Blum HE and Zoulim
F: Hepatitis C virus-induced hepatocarcinogenesis. J Hepatol.
51:810–820. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yamashita T, Honda M and Kaneko S:
Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C
virus infection. J Gastroenterol Hepatol. 26:960–964. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arzumanyan A, Reis HM and Feitelson MA:
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular
carcinoma. Nat Rev Cancer. 13:123–135. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moriya K, Fujie H, Shintani Y, Yotsuyanagi
H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T and
Koike K: The core protein of hepatitis C virus induces
hepatocellular carcinoma in transgenic mice. Nat Med. 4:1065–1067.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pan GJ, Chang ZY, Schöler HR and Pei D:
Stem cell pluripotency and transcription factor Oct4. Cell Res.
12:321–329. 2002. View Article : Google Scholar
|
|
7
|
Boyer LA, Lee TI, Cole MF, Johnstone SE,
Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG,
et al: Core transcriptional regulatory circuitry in human embryonic
stem cells. Cell. 122:947–956. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takahashi K, Tanabe K, Ohnuki M, Narita M,
Ichisaka T, Tomoda K and Yamanaka S: Induction of pluripotent stem
cells from adult human fibroblasts by defined factors. Cell.
131:861–872. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aoi T, Yae K, Nakagawa M, Ichisaka T,
Okita K, Takahashi K, Chiba T and Yamanaka S: Generation of
pluripotent stem cells from adult mouse liver and stomach cells.
Science. 321:699–702. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Freberg CT, Dahl JA, Timoskainen S and
Collas P: Epigenetic reprogramming of OCT4 and NANOG regulatory
regions by embryonal carcinoma cell extract. Mol Biol Cell.
18:1543–1553. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oskarsson T, Acharyya S, Zhang XH,
Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K,
Brogi E and Massagué J: Breast cancer cells produce tenascin C as a
metastatic niche component to colonize the lungs. Nat Med.
17:867–874. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Du Z, Jia D, Liu S, Wang F, Li G, Zhang Y,
Cao X, Ling EA and Hao A: Oct4 is expressed in human gliomas and
promotes colony formation in glioma cells. Glia. 57:724–733. 2009.
View Article : Google Scholar
|
|
13
|
Chiou SH, Wang ML, Chou YT, Chen CJ, Hong
CF, Hsieh WJ, Chang HT, Chen YS, Lin TW, Hsu HS, et al:
Coexpression of Oct4 and Nanog enhances malignancy in lung
adenocarcinoma by inducing cancer stem cell-like properties and
epithelial-mesenchymal transdifferentiation. Cancer Res.
70:10433–10444. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Arzumanyan A, Friedman T, Ng IO, Clayton
MM, Lian Z and Feitelson MA: Does the hepatitis B antigen HBx
promote the appearance of liver cancer stem cells? Cancer Res.
71:3701–3708. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou JJ, Chen RF, Deng XG, Zhou Y, Ye X,
Yu M, Tang J, He XY, Cheng D, Zeng B, et al: Hepatitis C virus core
protein regulates NANOG expression via the stat3 pathway. FEBS
Lett. 588:566–573. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou JJ, Deng XG, He XY, Zhou Y, Yu M, Gao
WC, Zeng B, Zhou QB, Li ZH and Chen RF: Knockdown of NANOG enhances
chemosensitivity of liver cancer cells to doxorubicin by reducing
MDR1 expression. Int J Oncol. 44:2034–2040. 2014.PubMed/NCBI
|
|
17
|
Hayashi H, Arao T, Togashi Y, Kato H,
Fujita Y, De Velasco MA, Kimura H, Matsumoto K, Tanaka K, Okamoto
I, et al: The OCT4 pseudogene POU5F1B is amplified and promotes an
aggressive phenotype in gastric cancer. Oncogene. 34:199–208. 2015.
View Article : Google Scholar
|
|
18
|
Yuan F, Zhou W, Zou C, Zhang Z, Hu H, Dai
Z and Zhang Y: Expression of Oct4 in HCC and modulation to
wnt/β-catenin and TGF-β signal pathways. Mol Cell Biochem.
343:155–162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li C, Yan Y, Ji W, Bao L, Qian H, Chen L,
Wu M, Chen H, Li Z and Su C: OCT4 positively regulates Survivin
expression to promote cancer cell proliferation and leads to poor
prognosis in esophageal squamous cell carcinoma. PLoS One.
7:e496932012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dai X, Ge J, Wang X, Qian X, Zhang C and
Li X: OCT4 regulates epithelial-mesenchymal transition and its
knockdown inhibits colorectal cancer cell migration and invasion.
Oncol Rep. 29:155–160. 2013.
|
|
21
|
Wang XQ, Ongkeko WM, Chen L, Yang ZF, Lu
P, Chen KK, Lopez JP, Poon RT and Fan ST: Octamer 4 (Oct4) mediates
chemotherapeutic drug resistance in liver cancer cells through a
potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology.
52:528–539. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ikushima H, Todo T, Ino Y, Takahashi M,
Saito N, Miyazawa K and Miyazono K: Glioma-initiating cells retain
their tumorigenicity through integration of the Sox axis and Oct4
protein. J Biol Chem. 286:41434–41441. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qian YW, Chen Y, Yang W, Fu J, Cao J, Ren
YB, Zhu JJ, Su B, Luo T, Zhao XF, et al: p28GANK
prevents degradation of Oct4 and promotes expansion of
tumor-initiating cells in hepatocarcinogenesis. Gastroenterology.
142:1547–58.e14. 2012. View Article : Google Scholar
|
|
24
|
Kim JB, Sebastiano V, Wu G, Araúzo-Bravo
MJ, Sasse P, Gentile L, Ko K, Ruau D, Ehrich M, van den Boom D, et
al: Oct4-induced pluripotency in adult neural stem cells. Cell.
136:411–419. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Beltran AS, Rivenbark AG, Richardson BT,
Yuan X, Quian H, Hunt JP, Zimmerman E, Graves LM and Blancafort P:
Generation of tumor-initiating cells by exogenous delivery of OCT4
transcription factor. Breast Cancer Res. 13:R942011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tsai LL, Hu FW, Lee SS, Yu CH, Yu CC and
Chang YC: Oct4 mediates tumor initiating properties in oral
squamous cell carcinomas through the regulation of
epithelial-mesenchymal transition. PLoS One. 9:e872072014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hui AM, Makuuchi M and Li X: Cell cycle
regulators and human hepatocarcinogenesis. Hepatogastroenterology.
45:1635–1642. 1998.PubMed/NCBI
|
|
28
|
Sundarrajan M, Gupta S and Rao KV:
Overexpression of cyclin D1 is associated with the decondensation
of chromatin during den-induced sequential hepatocarcinogenesis.
Cell Biol Int. 26:699–706. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sato Y, Kato J, Takimoto R, Takada K,
Kawano Y, Miyanishi K, Kobune M, Sato Y, Takayama T, Matunaga T, et
al: Hepatitis C virus core protein promotes proliferation of human
hepatoma cells through enhancement of transforming growth factor
alpha expression via activation of nuclear factor-kappaB. Gut.
55:1801–1808. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Han J, Zhang F, Yu M, Zhao P, Ji W, Zhang
H, Wu B, Wang Y and Niu R: RNA interference-mediated silencing of
NANOG reduces cell proliferation and induces G0/G1 cell cycle
arrest in breast cancer cells. Cancer Lett. 321:80–88. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sharov AA, Masui S, Sharova LV, Piao Y,
Aiba K, Matoba R, Xin L, Niwa H and Ko MS: Identification of
Pou5f1, Sox2, and Nanog downstream target genes with statistical
confidence by applying a novel algorithm to time course microarray
and genome-wide chromatin immunoprecipitation data. BMC Genomics.
9:2692008. View Article : Google Scholar : PubMed/NCBI
|
